No difference in expression of chromosomal fragile sites in patients with solid malignant tumours and normal controls
✍ Scribed by Thomas Kampmann; Angela Schmidt; Hugo W. Rüdiger; Tjhoen Lien Tan; Dr. Eberhard Passarge
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 262 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The frequency and distribution of rare and common chromosomal fragile sites in metaphases derived from peripheral lymphocytes were compared in 26 patients with malignant solid tumours and 24 normal controls. In order to avoid bias in evaluation, the identity of each individual as patient or control was disclosed only after the study was completed. Rare heritable folic acid inducible fragile sites were found in five patients (2q13; 6p23; 8q22; 16p12) and two controls (8q22). Common fragile sites were present in 21 of 26 patients and in 19 of 24 controls. These differences are statistically not significant in the Fisher test. We conclude that the expression of fragile sites does not indicate a predisposition for solid tumours.
📜 SIMILAR VOLUMES
## Abstract It has been suggested that common fragile sites (cFSs) are related to cancer development. This appears to be the case for FRA3B and FRA16D, localized in two tumor‐suppressor genes (__FHIT__ and __WWOX__, respectively) that are altered by deletions or loss of heterozygosity (LOH) in many